Transfluthrin

DB15117InvestigationalSmall molecule

Transfluthrin is under investigation in clinical trial NCT02394522 (Spatial Repellent Products for Control of Vector Borne Diseases - Malaria - Zambia (SR-M-ZM)).

Mechanism: Pharmacologically active on Voltage-gated sodium channel alpha subunit
Curator reviewed
Formula / weight: C₁₅H₁₂Cl₂F₄O₂ · 371.15 g/mol (avg)

Resolves to

Compound

UNIIQWL3SKA6EGCAS118712-89-3ChEMBLCHEMBL3184657ChEBI32253KEGGC13410

Structure

InChIKeyDDVNRFNDOPPVQJ-HQJQHLMTSA-NSMILESCC1(C)[C@H](C=C(Cl)Cl)[C@H]1C(=O)OCC1=C(F)C(F)=CC(F)=C1F

What you can answer from here — as of August 28, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which companies are running trials of Transfluthrin, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account